Endometrial Cancer
Clinical research in advanced and recurrent endometrial cancer, with attention to TP53 wild-type disease and maintenance therapy strategies.
- Advanced or recurrent endometrial cancer
- TP53 wild-type tumour biology
- Maintenance treatment
Interest centres on disease control in patients with persistent or returning endometrial malignancy.
Myelofibrosis
Extensive activity in myelofibrosis, including primary myelofibrosis, secondary myelofibrosis, and post–polycythemia vera and post–essential thrombocythemia forms.
- Primary myelofibrosis
- Post–PV-MF and post–ET-MF
- Secondary myelofibrosis
Research also addresses intermediate- and high-risk disease patterns and patients with relapsed or refractory disease.
JAK Inhibitor–Related Disease
Trials focus on patients with myelofibrosis who have had an inadequate response to JAK inhibitor treatment, including settings where ruxolitinib is part of the therapeutic landscape.
- Relapsed or refractory myelofibrosis
- Suboptimal response to ruxolitinib
- JAK inhibitor treatment failure
This area reflects a focus on patients whose symptom burden and disease control remain challenging after standard targeted therapy.
Spleen and Symptom Outcomes
Several studies emphasize spleen volume reduction, spleen response, and total symptom score improvement in myelofibrosis.
- Spleen volume reduction
- Spleen response
- Total symptom score
These endpoints align with the clinical management of splenomegaly and symptom relief in chronic myeloid disorders.
